ReviewHarvard review of psychiatry
Glutamatergic modulators: the future of treating mood disorders?
Review in Harvard review of psychiatry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed.
- Ketamine normalizes brain activity during emotionally valenced attentional processing in depression.NeuroImage. Clinical · 2018Trial
- A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression.Journal of clinical psychopharmacology · 2017Trial
- Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.Journal of Parkinson's disease · 2017Trial
- Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.CNS drugs · 2026Review
- Astroglial kappa opioid receptor-mediated reduction of glutamate exchanger xCT in the prelimbic cortex underlies chronic stress-induced depressive-like behaviors.Molecular psychiatry · 2026Article
- Plasma Metabolic and Inflammatory Protein Signatures in Psychiatric Disorders.International journal of molecular sciences · 2025Article
- The neuropsychopharmacology of acetyl-L-carnitine (LAC): basic, translational and therapeutic implications.Discover mental health · 2024Review
- Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?Psychopharmacology · 2023Article
- Variation along P2RX7 interacts with early traumas on severity of anxiety suggesting a role for neuroinflammation.Scientific reports · 2023Article
- The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?Advances in experimental medicine and biology · 2023Article
- The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.Journal of midwifery & women's health · 2022Review
- Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Carnitine and Depression.Frontiers in nutrition · 2022Review
- Blood Glutamate Scavenging With Pyruvate as a Novel Preventative and Therapeutic Approach for Depressive-Like Behavior Following Traumatic Brain Injury in a Rat Model.Frontiers in neuroscience · 2022Article
- Impact of SAfinamide on Depressive Symptoms in Parkinson's Disease Patients (SADness-PD Study): A Multicenter Retrospective Study.Brain sciences · 2021Article
- Glutamatergic Correlates of Bipolar Symptoms in Adolescents.Journal of child and adolescent psychopharmacology · 2020Article
- Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis.Archives of toxicology · 2020Article
- SIRT1 in forebrain excitatory neurons produces sexually dimorphic effects on depression-related behaviors and modulates neuronal excitability and synaptic transmission in the medial prefrontal cortex.Molecular psychiatry · 2020Article
- Organ-level protein networks as a reference for the host effects of the microbiome.Genome research · 2020Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mood disorders such as bipolar disorder and major depressive disorder are common, chronic, and recurrent conditions affecting millions of individuals worldwide. Existing antidepressants and mood stabilizers used to treat these disorders are insufficient for many. Patients continue to have low remission rates, delayed onset of action, residual subsyndromal symptoms, and relapses. New therapeutic agents able to exert faster and sustained antidepressant or mood-stabilizing effects are urgently needed to treat these disorders. In this context, the glutamatergic system has been implicated in the pathophysiology of mood disorders in unique clinical and neurobiological ways. In addition to evidence confirming the role of the glutamatergic modulators riluzole and ketamine as proof-of-concept agents in this system, trials with diverse glutamatergic modulators are under way. Overall, this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.